Boundless Bio, Inc. Common Stock (BOLD)

Boundless Bio, Inc. Common Stock (BOLD) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $58.5M; returns 1 day -3.3%, 1 week +0.9%, 1 year +67.4%.

Boundless Bio Inc. is a clinical-stage oncology company dedicated to discovering and developing novel therapeutics that target oncogene amplified cancers, primarily by addressing the role of extrachromosomal DNA (ecDNA). The company's business model revolves entirely around its research and development pipeline, as it currently has no approved products and generates no revenue.

Groups BOLD belongs to

• Biotechnology
• Clinical Stage Biotech
• Oncology
• Healthcare
• Cancer Therapeutics
• Life Sciences
• R&D
• Precision Medicine

BOLD financial model: income statement, cash flow and balance sheet